From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Mass Spec Innovations Bring 10M Back to PNNL, Battelle

by Global Biodefense Staff
April 3, 2015
Yehia Ibrahim - PNNL Mass Spectrometry Innovations

Yehia Ibrahim is part of a PNNL team that developed the new Ion Mobility Spectrometry-Mass Spectrometry Proteomics system.

A suite of analytical innovations used to detect and measure very low levels of compounds and elements for environmental, national security and health applications has topped $10 million in licensing income for Pacific Northwest National Laboratory and its operator Battelle.

Since 1989, dozens of PNNL researchers have been enhancing the performance of mass spectrometers — at first for use in PNNL’s own environmental, national security and health-related research programs, and then as part of efforts to improve the science impact of mass spectrometers in the marketplace.

Mass spectrometry is an ultra-sensitive analytical technique that helps identify and measure the amount and type of elements, molecules and isotopes present in samples ranging from soils to proteins. It’s widely used to analyze samples in the biotechnology, environmental, biofuel, national security, medical and drug testing fields. The technology is used in early detection of disease biomarkers and environmental contaminants, quality assurance and the development of new products.

Through licenses, PNNL has transferred the technology enhancements to many companies, including Agilent Technologies in Santa Clara, Calif.; Bruker Daltonics in Billerica, Mass.; Thermo Fisher Scientific in San Jose, Calif., and several others. These firms are manufacturing and selling mass spectrometers to customers worldwide.

Most of the money from these agreements has been directly reinvested in new research programs, demonstration projects, laboratory equipment and staff at the Department of Energy national laboratory in Richland, or reinvested by Battelle in research-related activities consistent with its non-profit mission.

It’s the first time that income tied to a specific technology developed at PNNL has reached this level. The income was earned from multiple licenses over nearly a 20-year period. The annual amount has steadily increased over the past five years.

“Based upon the royalty rates in the various licenses, it is estimated that the royalties received by PNNL represent more than 5,000 mass spectrometer instruments sold to date that were based in part on PNNL intellectual property,” said Bruce Harrer, a PNNL commercialization manager.

“We’ve benefited greatly from PNNL’s developments,” said John Fjeldsted, Agilent Technology’s senior director of ion mobility for Agilent’s Mass Spectrometry Division. “One of the PNNL technologies — the ion funnel — has made significant contributions to the sensitivity of our top-tier products, including those involving ion mobility and time-of-flight measurements.”

PNNL works with mass spectrometer manufacturers to develop and commercialize these technologies through an active program of collaborative research and development projects. “We have had a number of collaborative R&D projects with PNNL over the past 20 years, many of which have led to important advances in the field,” said Iain Mylchreest, vice president for research and development in Thermo Fisher’s Chromatography and Mass Spectrometry Division.

Under Battelle’s contract to manage and operate PNNL for DOE, Battelle and DOE may share the costs of bringing a technology to the point that it can be licensed and then share in any proceeds. This long-term partnership has enabled substantial reinvestment in the form of new research projects and additional capabilities at PNNL, such as new mass spectrometer instruments.

“In addition to advancing scientific discovery, this arrangement is a win-win for taxpayers, DOE and Battelle,” said Cejka. “Taxpayers and society at large benefit from the deployment of new products in the marketplace. The government benefits from the investments made into federally-owned laboratory capabilities. Battelle benefits from the reinvestment of net proceeds into new facilities, equipment, staff capabilities or further research and technology development projects.”

Images courtesy of Pacific Northwest National Laboratory.

From Our Partners
Tags: BattelleBiomarkers

Related Posts

Influenza Research
Biodetection

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
BARDA and JPEO-CBRND Back Cepheid’s Multiplex Test for Influenza, SARS-CoV2 and RSV
Health Security

Resurgent COVID-19, Flu and Other Viruses are Pushing New Zealand’s Health System to the Limit

June 2, 2022
NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools
Biodetection

Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

May 6, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC